Psoriasis is a chronic, systemic, immune-mediated disease, with prominent skin 
and joint manifestations, associated with several comorbidities. In the past few 
decades, advances in the knowledge of psoriasis pathogenesis have driven the 
development of highly effective targeted biologic therapies, transforming the 
treatment landscape of psoriasis. Bimekizumab is a humanized antibody that 
selectively binds and neutralizes the biologic functions of interleukin (IL)-17A 
and IL-17F. This article reviews the current knowledge about bimekizumab in 
psoriasis treatment. The results obtained in the phase 3 studies (BE VIVID, BE 
READY, BE RADIANT, BE SURE) corroborate the high levels of efficacy of 
bimekizumab seen in previous studies, and show superior efficacy over 
adalimumab, ustekinumab, and secukinumab in direct comparative studies. In all 
phase 3 trials, bimekizumab was also well tolerated, with a safety profile 
similar to the other biologic drugs tested, except for a higher frequency of 
oral candidiasis. Dual inhibition of IL-17A and IL-17F is a highly effective 
therapeutic option for the treatment of psoriasis, both for naïve patients and 
for those resistant to previous biologic treatments.